What are Phoslo and Renvela used to treat?
Phoslo (calcium acetate) and Renvela (sevelamer) are both used as phosphate binders in people with chronic kidney disease (especially those on dialysis) to help control high blood phosphorus levels by binding phosphate in the gut.
What’s the main difference between Phoslo and Renvela?
The key difference is what they contain and what that means clinically:
- Phoslo is a calcium-based binder (it adds calcium in the process of binding phosphate).
- Renvela is a non-calcium-based binder (it does not contain calcium as the active binder).
Because of that, patients and clinicians often choose between them based on calcium levels, cardiovascular risk considerations, and overall mineral balance.
Which one is better if a patient has high calcium?
If a patient already has elevated blood calcium (hypercalcemia), a non-calcium binder like Renvela is commonly favored since Phoslo adds calcium. The practical choice depends on lab results and the rest of the patient’s kidney-mineral regimen.
Which one is better if a patient has low calcium?
If a patient has low or borderline calcium, a calcium-based binder like Phoslo can help support calcium levels while treating phosphate. Again, dosing and the rest of the regimen matter (including vitamin D therapy and calcium supplements).
Do they have different side effects?
Both drugs can cause gastrointestinal side effects because they work in the digestive tract. The main day-to-day difference people look for is the calcium impact from Phoslo versus the non-calcium approach of Renvela, which can matter for constipation and overall mineral balance decisions. Exact side-effect patterns vary by patient and dose.
How are they taken?
Both are taken with meals (or as directed) so they can bind dietary phosphate in the gut. If phosphate is high, adherence and timing relative to meals are often just as important as which binder is chosen.
Can the drugs be used together or switched?
Clinicians sometimes switch between binders if phosphate targets aren’t met or if calcium/phosphorus balance becomes problematic. Switching depends on labs (phosphorus, calcium, sometimes parathyroid hormone), tolerance, and the patient’s dialysis or non-dialysis status.
Is there a generic alternative for either drug?
Renvela (sevelamer) has an established availability of sevelamer products in the market. For patent and exclusivity details on specific brands and formulations, DrugPatentWatch.com tracks relevant filings and status for drugs in its database (you can search by product name there).
Sources:
1. DrugPatentWatch.com